DexCom, Inc.
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
About
CEO
Mr. Kevin Ronald Sayer
Employees
9,500
Instrument type
Common Stock
Sector
Healthcare
Industry
Medical Devices
MIC code
XNGS
Address
6340 Sequence Drive, San Diego, CA 92121, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 22, 2025 | — | — | — | — |
| Jul 23, 2025 | — | — | — | — |
| Apr 23, 2025 | — | — | — | — |
| Feb 7, 2025 | 0.52 | — | — | — |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 16 | — | 21 |
| Average estimate | — | 0.38 | — | 2.01 |
| Low estimate | — | 0.32 | — | 1.77 |
| High estimate | — | 0.45 | — | 2.22 |
| Last year EPS | — | 0.32 | — | 1.69 |
[stock_revenue_estimate]
Growth estimates
Current qtr
0.070%
Next qtr. (Mar 2025)
18.500%
Current year
11.020%
Next year (Dec 2025)
19.170%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 3.62B | 2.91B | 2.45B | 1.93B | 1.48B |
| Cost of revenue | 1.33B | 1.03B | 768.00M | 646.60M | 544.50M |
| Gross profit | 2.29B | 1.88B | 1.68B | 1.28B | 931.50M |
| Operating expense | |||||
| Research & development | 505.80M | 484.20M | 604.20M | 359.90M | 273.50M |
| Selling general and admin | 1.19B | 1.01B | 810.50M | 620.70M | 515.70M |
| Other operating expenses | — | — | — | — | — |
| Operating income | 597.70M | 391.20M | 265.80M | 299.50M | 142.30M |
| Non operating interest income | |||||
| Income | 135.00M | 23.80M | 1.70M | 16.10M | 26.40M |
| Expense | 20.30M | 18.60M | 18.80M | 84.70M | 60.30M |
| Other income expense | -2.00M | -5.60M | 8.10M | -5.90M | -4.20M |
| Pretax income | 710.40M | 390.80M | 256.80M | 225.00M | 104.20M |
| Tax provision | 168.90M | 49.60M | 39.90M | -268.60M | 3.10M |
| Net income | 541.50M | 341.20M | 216.90M | 493.60M | 101.10M |
| Basic EPS | 1.40 | 0.88 | 0.40 | 1.31 | 0.28 |
| Diluted EPS | 1.30 | 0.82 | 0.39 | 1.27 | 0.28 |
| Basic average shares | 386.00M | 389.40M | 386.80M | 377.60M | 364.40M |
| Diluted average shares | 386.00M | 389.40M | 386.80M | 377.60M | 364.40M |
| EBITDA | 916.70M | 565.30M | 377.70M | 382.70M | 213.20M |
| Net income from continuing op. | 541.50M | 341.20M | 216.90M | 493.60M | 101.10M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 6.26B | 5.39B | 4.93B | 4.29B | 2.40B |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 566.30M | 642.30M | 1.05B | 817.60M | 446.20M |
| Other short term investments | 2.16B | 1.81B | 1.68B | 1.89B | 1.09B |
| Accounts receivable | 973.90M | 713.30M | 514.30M | 428.50M | 286.30M |
| Other receivables | — | — | — | — | — |
| Inventory | 559.60M | 306.70M | 357.30M | 234.70M | 119.80M |
| Prepaid assets | 90.20M | 116.70M | 51.90M | 53.90M | 30.00M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 49.30M | 26.80M | 27.40M | 53.90M | 30.00M |
| Non current assets | |||||
| Properties | 71.40M | 80.00M | 88.10M | 93.30M | 71.50M |
| Land and improvements | 34.50M | 26.90M | 15.60M | 15.60M | — |
| Machinery furniture equipment | 786.00M | 530.60M | 356.30M | 249.90M | 175.70M |
| Construction in progress | 328.10M | 542.60M | 360.70M | 219.00M | 132.60M |
| Leases | 283.40M | 264.40M | 251.60M | 135.80M | 102.50M |
| Accumulated depreciation | -509.40M | -363.20M | -231.50M | -154.20M | -105.00M |
| Goodwill | 184.90M | 224.70M | 84.50M | 60.00M | 37.20M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 134.50M | 173.30M | 31.50M | 21.40M | — |
| Investments and advances | 38.50M | 19.00M | — | — | — |
| Other non current assets | 441.50M | 353.10M | 301.00M | 237.80M | 14.20M |
| Total liabilities | 4.20B | 3.26B | 2.89B | 2.46B | 1.51B |
| Current liabilities | |||||
| Accounts payable | 276.40M | 237.90M | 189.40M | 163.30M | 102.30M |
| Accrued expenses | 1.14B | 705.70M | 419.80M | 390.20M | 228.60M |
| Short term debt | 21.10M | 793.10M | 20.50M | 16.50M | 13.60M |
| Deferred revenue | 33.60M | 20.30M | 2.10M | 2.20M | 1.70M |
| Tax payable | 50.10M | 44.80M | 40.60M | 15.30M | 14.00M |
| Pensions | 31.20M | 37.50M | 33.40M | 26.60M | — |
| Other current liabilities | — | — | 15.00M | — | — |
| Non current liabilities | |||||
| Long term debt | 2.57B | 1.35B | 2.14B | 1.82B | 1.15B |
| Provision for risks and charges | 38.70M | 32.70M | 2.80M | — | — |
| Deferred liabilities | — | 4.90M | 5.90M | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 5.20M | 5.90M | 8.20M | 26.90M | 5.70M |
| Shareholders equity | |||||
| Common stock | 400,000 | 400,000 | 400,000 | 100,000 | 100,000 |
| Retained earnings | 1.02B | 479.90M | 138.70M | -202.10M | -695.70M |
| Other shareholders equity | -16.70M | -11.60M | 500,000 | 3.20M | 2.30M |
| Total shareholders equity | 2.07B | 2.13B | 2.04B | 1.83B | 882.60M |
| Additional paid in capital | 3.51B | 2.26B | 2.11B | 2.13B | 1.68B |
| Treasury stock | 2.45B | 595.00M | 206.20M | 100.00M | 100.00M |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||
| Net Income | 541.50M | 341.20M | 216.90M | 493.60M | 101.10M | -127.10M | -50.20M | -65.60M | -57.60M | -22.40M | -29.80M | -54.50M | -44.70M | -55.20M | -53.52M | -58.86M | -45.88M | -46.60M | -30.77M | -13.95M | -9.91M |
| Depreciation | 186.00M | 155.90M | 102.00M | 67.10M | 48.70M | 29.10M | 16.10M | 15.00M | 10.80M | 8.40M | 7.00M | 6.60M | 3.80M | 2.40M | 2.37M | 3.04M | 3.33M | 2.70M | 1.07M | 486,805 | 353,550 |
| Deferred Taxes | -55.00M | -21.60M | 15.80M | -277.30M | 200,000 | -2.20M | — | — | — | — | — | -1.30M | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 150.80M | 126.50M | 113.40M | 119.40M | 102.70M | 101.90M | 106.20M | 110.80M | 82.70M | 50.00M | 24.60M | 18.40M | 13.50M | 9.40M | 8.37M | — | — | — | — | — | — |
| Other Non-Cash Items | -76.10M | 41.00M | 137.90M | 87.70M | 51.50M | 242.50M | 17.30M | 2.30M | 37.50M | 200,000 | 3.10M | 800,000 | -31.23M | 1.10M | 4.75M | 12.10M | 5.63M | 5.48M | — | — | — |
| Accounts Receivable | -260.10M | -199.90M | -75.50M | -142.30M | -60.00M | -93.20M | -31.80M | -27.20M | -31.70M | -16.30M | -6.50M | -7.00M | -5.90M | -3.20M | -2.37M | -903,000 | -95,000 | -120,000 | — | — | — |
| Accounts Payable | 466.50M | 295.10M | 58.00M | 194.50M | 109.00M | 56.20M | 21.10M | 21.10M | 17.80M | 8.30M | 2.40M | 300,000 | 1.00M | -400,000 | 1.51M | — | — | — | — | — | — |
| Other Assets & Liabilities | -259.70M | 54.60M | -103.60M | -96.70M | -51.70M | -24.70M | 5.20M | -4.80M | -15.70M | -6.20M | -3.10M | 1.70M | -1.00M | -8.70M | -2.66M | 3.80M | 1.71M | -1.44M | 625,744 | 34,192 | -21,011 |
| Operating Cash Flow | 693.90M | 792.80M | 464.90M | 446.00M | 301.50M | 182.50M | 83.90M | 51.60M | 43.80M | 22.00M | -2.30M | -35.00M | -64.53M | -54.60M | -41.57M | -40.82M | -35.30M | -39.98M | -29.08M | -13.43M | -9.58M |
| Investing Activities | |||||||||||||||||||||
| Capital Expenditures | -236.60M | -364.80M | -389.20M | -199.00M | -180.00M | -67.10M | -66.00M | -55.70M | -33.30M | -16.20M | -7.90M | -9.50M | -8.00M | -6.90M | -2.69M | -2.49M | -3.44M | -3.35M | -4.68M | -1.76M | -408,609 |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | -3.90M | -30.20M | — | — | -11.30M | — | 300,000 | -500,000 | — | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -3.20B | -2.27B | -2.47B | -3.06B | -2.03B | -452.50M | -171.80M | -39.20M | -45.20M | -13.80M | -16.30M | -66.40M | -102.70M | -73.40M | -65.27M | -36.99M | -76.94M | -61.73M | -31.57M | — | — |
| Sale of Investments | 2.95B | 2.13B | 2.67B | 2.25B | 1.20B | 392.10M | 93.40M | 38.70M | 27.50M | 13.20M | 45.10M | 104.30M | 64.30M | 54.70M | 53.86M | 63.80M | 71.94M | 38.53M | 18.08M | — | 7.77M |
| Investing Cash Flow | -507.20M | -521.50M | -216.10M | -1.02B | -1.02B | -139.80M | -144.40M | -55.90M | -51.50M | -16.80M | 20.90M | 28.40M | -46.40M | -25.60M | -14.10M | 24.32M | -8.44M | -26.56M | -18.17M | -1.74M | 7.37M |
| Financing Activities | |||||||||||||||||||||
| Long-Term Debt Issuance | 1.23B | — | — | 1.19B | — | 836.60M | 389.00M | — | — | — | — | 6.60M | — | — | — | 3.00M | — | — | — | — | — |
| Long-Term Debt Payments | -787.30M | — | — | -282.60M | — | — | -75.00M | — | -2.30M | -2.20M | -200,000 | — | -500,000 | -900,000 | -1.93M | -2.05M | — | — | — | — | — |
| Other Financing Charges | -99.80M | -17.30M | -9.90M | -9.40M | -1.20M | -220.80M | — | -2.30M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing Cash Flow | -318.60M | -552.50M | 10.40M | 912.10M | 10.70M | 526.60M | 324.10M | 8.10M | 16.80M | 21.80M | 11.80M | 10.20M | 74.20M | 69.60M | 44.38M | 2.71M | -1.83M | 48.19M | 50.74M | 21.38M | 33,440 |
| Other Cash Details | |||||||||||||||||||||
| End Cash Position | 567.50M | 643.30M | 1.05B | 818.20M | 446.40M | 1.14B | 441.50M | 94.50M | 86.10M | 71.80M | 43.20M | 8.10M | 2.60M | 4.90M | 3.58M | 12.70M | 23.12M | 18.17M | 37.25M | 27.23M | 20.02M |
| Income Tax Paid | 212.30M | 114.20M | 16.80M | 3.60M | 4.80M | 2.30M | 1.40M | 100,000 | 100,000 | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 12.40M | 12.20M | 11.60M | 10.60M | 10.40M | 3.60M | 2.40M | 100,000 | 300,000 | 400,000 | 500,000 | — | — | 400,000 | 2.93M | 3.07M | — | — | — | — | — |
| Free Cash Flow | 511.90M | 304.70M | 53.30M | 276.60M | 134.50M | 56.10M | 26.00M | 500,000 | 15.70M | 7.40M | -5.50M | -42.60M | -38.10M | -49.60M | -42.38M | -39.94M | -36.65M | -47.09M | -27.23M | -14.19M | -9.87M |
Error: Invalid format in Holders JSON file.
Article
Countdown to DexCom (DXCM) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of DexCom (DXCM) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Feb 10, 2025
Article
Should You Buy DexCom Stock Before Feb. 13?
DexCom (DXCM 1.51%) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track glucose levels.
Feb 6, 2025
Article
Prediction: This Top Growth Stock Will Outperform the Market in the Next Decade
Medical device specialist DexCom (DXCM -0.90%) has substantially underperformed the market over the trailing-12-month period. The diabetes-focused company disappointed investors last year due to unimpressive financial results, especially in the second and third quarters.
Feb 3, 2025
